Showing results (451-460 of 2,733) with videos related to
Sort By:
Pageof 274
Pharmacogenomics|October 4, 2013
Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trialDaniel E Jonas, James P Evans, Howard L McLeod, et al.Pharmacogenomics|October 4, 2013
Long-term effects of ABCB1 and SXR SNPs on the systemic exposure to cyclosporine in pediatric kidney transplant patientsMariano Ferraresso, Mirco Belingheri, Stefano Turolo, et al.Pharmacogenomics|October 4, 2013
Impact of biomarkers on clinical trial riskGeoffrey Gilbert John Reid, Tarek Abdullah Bin Yameen, Jayson Lee ParkerPharmacogenomics|July 11, 2013
Tacrolimus dose requirement in pediatric liver transplantation: influence of CYP3A5 gene polymorphismPhilippe Durand, Dominique Debray, Mikaela Kolaci, et al.Pharmacogenomics|July 11, 2013
Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimenCindy Serdjebi, Jean-François Seitz, Joseph Ciccolini, et al.Pharmacogenomics|July 11, 2013
Pharmacogenetics in solid organ transplantation: genes involved in mechanism of action and pharmacokinetics of immunosuppressive drugsMateusz Kurzawski, Marek DroździkPharmacogenomics|July 18, 2013
SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysisBatoul Sadat Haerian, Larry Baum, Patrick Kwan, et al.Pharmacogenomics|July 18, 2013
Impact of pharmacogenetics on CNS side effects related to efavirenzAlmudena Sánchez Martín, Salvador Cabrera Figueroa, Raquel Cruz Guerrero, et al.Pharmacogenomics|July 18, 2013
Pharmacogenetics of chronic obstructive pulmonary diseaseNobuyuki HizawaPharmacogenomics|January 20, 2012
Pharmacogenetics of drugs withdrawn from the marketWei Zhang, Mary W Roederer, Wang-Qing Chen, et al.Pageof 274